Alik Farber, MD
James Utley Professor and Chair of Surgery
Boston University Chobanian & Avedisian School of Medicine

MD, Harvard Medical School
MBA, Brandeis University
BS, Brown University



Dr. Alik Farber is the Surgeon-in-Chief at BMC. He is also the James Utley Professor and Chair of Surgery at Boston University Chobanian & Avedisian School of Medicine.

Dr. Farber is an expert in vascular and endovascular intervention to treat peripheral arterial disease, open and endovascular abdominal and thoracic aortic aneurysm repair, the treatment of diabetic foot problems, carotid artery surgery and stenting, and dialysis access. He is a prolific researcher who has published more than 260 peer-reviewed articles and has served as a principal investigator (PI) for a number of clinical trials, including the recently completed BEST-CLI (Best Endovascular versus Best Surgical Therapy in Patients with Critical Limb Ischemia) trial. Dr. Farber was a national PI for this international, randomized controlled trial.

Dr. Farber received his medical degree from Harvard Medical School and bachelor's degree from Brown University. He completed his residency in general surgery at Massachusetts General Hospital; a vascular surgery fellowship at Dartmouth-Hitchcock Medical Center; and an endovascular surgery fellowship at Southern Illinois School of Medicine. Dr. Farber is a member of numerous national and regional medical and surgical societies.

Surgeon-in-Chief
Boston Medical Center


Professor
Boston University Chobanian & Avedisian School of Medicine
Surgery
Vascular and Endovascular Surgery

Associate Chief Medical Officer for Surgical Services
Boston Medical Center


Professor
Boston University Chobanian & Avedisian School of Medicine
Radiology
Vascular & Interventional

Member
Boston University
Evans Center for Interdisciplinary Biomedical Research




Impact of Biological, Clinical, and Social Determinants on Trauma and Trauma Outcomes
07/01/2022 - 06/30/2027 (PI)
NIH/National Institute of General Medical Sciences
5T32GM086308-14

A Prospective, Single-blind, Randomized, Phase III Study to Evaluate the Safety and Efficacy of Fibrin Sealant Grifols
05/01/2012 - 12/31/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm^2 to <= 36 cm^2
10/15/2013 - 08/30/2015 (PI)
HealthPoint Limited


A Non-Interventional Safety Study Providing 12 Months Follow-Up from First Exposure to HP802-247 in Subjects with Venous Leg Ulcer
05/01/2012 - 04/30/2015 (PI)
HealthPoint Limited


Observational Study of Tissue Plasminogen Activator Used for Catheter Directed Thrombolysis in Patients with Acute Lower Extremety Native Artery or Bypass Graft Occlusion
01/27/2014 - 01/26/2015 (PI)
Grifols Inc.


A Phase 3 Randomized, Double Blind, Vehicle Controlled Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers
05/01/2012 - 04/30/2014 (PI)
HealthPoint Limited


Vital Access Venous Window Needle Guide for salvage of AV Fistulae (SAVE) Trial
08/15/2012 - 08/14/2013 (PI)
Vital Access Corp


IN-BALANCE VLU (Inflammation, Bacteria, and Angiogenesis effects in launching venous leg ulcer healing: a clinical evaluation)
08/01/2012 - 07/31/2013 (PI)
Celleration, Inc.


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


A Phase 2 randomized open label study to evaluate the effects of different intra-thrombus infusion regiments of plasmin humun compared to placebo
08/01/2011 - 07/31/2012 (PI)
Talecris Pharmaceuticals


Showing 10 of 17 results. Show All Results

Peripheral Bypass Trial for Completion Control
11/08/2024 - 11/07/2027 (PI)
Medistim ASA

Assessment of Wound Closure Comparing Synthetic Hybrid- Scale Fiber Matrix with Lyophilized Acellular Fish Skin in Treating Diabetic Foot Ulcers (DFU) and with Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)
10/12/2022 - 10/12/2025 (PI)
Acera Surgical Inc.


Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (Best-CLI)
09/01/2022 - 08/31/2025 (Subcontract PI)
PI: Alik Farber, MD
Brigham and Womens Hospital Novo Nordisk Fdn


A multi-center prospective study to evaluate the safety and effectiveness of the VasQ external suppo
11/01/2017 - 01/31/2025 (PI)
Laminate Medical Technologies Inc.


LF-CA-PR-53-PROMISE III Trial
12/09/2022 - 10/31/2024 (PI)
LimFlow Inc


A Pivotal Study to Investigate the Safety and Effectiveness of the Limflow System for the…
12/11/2019 - 10/31/2024 (PI)
LimFlow Inc


Novonordisk-NN9535-4533
09/14/2021 - 09/14/2024 (PI)
Novo Nordisk


A comparative evaluation of a marine polysaccharide dressing and a carboxymethylcellulose dressing on subjects with lower extremity venous ulcerss
10/14/2020 - 10/14/2023 (PI)
Medline Industries LLC


Natural Progression of High-Risk Chronic Limb-Threatening Ischemia. The CLariTI Study.
03/25/2021 - 08/31/2023 (PI)
LimFlow Inc


A multicenter, prospective, randomized, placebo controlled, double blind study performed to…
09/24/2019 - 08/31/2023 (PI)
MediWound Ltd.


Showing 10 of 20 results. Show All Results

Title

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Website       Copy PMIDs To Clipboard

  1. Shishehbor MH, Dua A, Powell RJ, Montero-Baker MF, Martínez-Trabal JL, Bunte MC, Lee AC, Mills JL, Farber A, Clair DG. Two-Year Outcomes after Transcatheter Arterialization of the Deep Veins. N Engl J Med. 2025 Oct 30; 393(17):1751-1753. PMID: 41160827; DOI: 10.1056/NEJMc2507935;
     
  2. Zhou CW, Hoch M, Freeman NLB, Menard MT, Farber A, Chung J, Kosorok MR, McGinigle KL. Using Precision Medicine Methods to Identify Disease Stages for Chronic Limb-Threatening Ischemia in Participants of the BEST-CLI Trial. J Vasc Surg. 2025 Oct 28. PMID: 41167383; DOI: 10.1016/j.jvs.2025.10.029;
     
  3. Rahgozar S, Hamouda M, Farber A, Menard MT, Ilyas S, Malas MB. Predictors of Surgical Site Infection Following Infra-Inguinal Bypass Surgery: An Analysis of the Vascular Quality Initiative Data. J Vasc Surg. 2025 Oct 22. PMID: 41135721; DOI: 10.1016/j.jvs.2025.10.023;
     
  4. Patel N, Schneider A, Cheng TW, Alonso A, McNamara T, Maaneb De Macedo K, King E, Farber A, Siracuse JJ. Educational Attainment and Outcomes of Hemodialysis Access Creation. Vasc Endovascular Surg. 2025 Oct 15; 15385744251387567.View Related Profiles. PMID: 41091004; DOI: 10.1177/15385744251387567;
     
  5. Farber A, Menard MT, Siracuse JJ. Were Bridges Burned or was the Deck Stacked? Eur J Vasc Endovasc Surg. 2025 Sep 29.View Related Profiles. PMID: 41033637; DOI: 10.1016/j.ejvs.2025.09.053;
     
  6. Venermo MA, Farber A. The SWEDEPAD Trials: Not Just Another Set of Neutral Trials, but a Wake Up Call. Eur J Vasc Endovasc Surg. 2025 Sep 29. PMID: 41033644; DOI: 10.1016/j.ejvs.2025.09.058;
     
  7. McNamara T, Zhu M, Rodriguez D, Arinze N, Cheng TW, Farber A, King EG, Kalish J, Maaneb de Macedo K, Alonso A, Siracuse JJ. Association of food and housing insecurity with outcomes after revascularization for chronic limb-threatening ischemia. J Vasc Surg. 2025 Sep 10.View Related Profiles. PMID: 40939901
     
  8. Patel N, Farber A, King E, Malas M, Alonso A, Chitalia V, Lotfollahzadeh S, Columbo JA, Goodney PP, Siracuse JJ. Upper Extremity Arteriovenous Grafts are Less Likely to be Abandoned Compared to Autogenous Fistulas Despite a Higher Reintervention Rate. Ann Vasc Surg. 2025 Sep 03; 121:654-663.View Related Profiles. PMID: 40912639
     
  9. Alameddine D, Hamouda M, Doros G, Conte MS, Rosenfield K, Strong MB, Menard MT, Farber A, Hamdan A, Malas M, Ochoa Chaar CI. Insulin therapy and outcomes of revascularization procedures for chronic-limb threatening ischemia in the BEST-CLI trial. J Vasc Surg. 2025 Aug 29.View Related Profiles. PMID: 40886741; DOI: 10.1016/j.jvs.2025.08.033;
     
  10. Jones DW, Farber A, Armstrong DG, Azene E, Duncan A, Todoran TM, Doros G, Strong MB, Rosenfield K, Conte MS, Menard MT. Characteristics of multidisciplinary limb preservation teams and their impact on outcomes in the BEST-CLI trial. J Vasc Surg. 2025 Aug 28.View Related Profiles. PMID: 40885461; PMCID: PMC12416768; DOI: 10.1016/j.jvs.2025.08.028;
     
Showing 10 of 409 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 408 publications over 27 distinct years, with a maximum of 41 publications in 2016

YearPublications
19921
19931
19992
20011
20022
20033
20044
20051
20073
20082
20096
20104
201112
20129
201319
201415
201521
201641
201738
201840
201925
202036
202119
202214
202323
202427
202539

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
Contact for Mentoring:

85 E. Concord St.
Boston MA 02118
Google Map


Farber's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Media Mentions
_
Co-Authors
_
Similar People
_